Valuation: Orexo AB

Market Cap 510M 53.39M 46.38M 43.07M 39.72M 74.81M 5.1B 76.17M 200M 2.53B 201M 196M 8.51B P/E 2026 *
-1.39x
P/E 2027 * -2.01x
Enterprise Value 405M 42.4M 36.83M 34.2M 31.54M 59.41M 4.05B 60.48M 159M 2.01B 159M 156M 6.76B EV / Sales 2026 *
21.3x
EV / Sales 2027 * 13.3x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 day+1.58%
1 week-3.15%
Current month-38.50%
1 month-37.46%
3 months-20.65%
6 months-50.47%
Current year-50.96%
1 week 13.7
Extreme 13.7
15.52
1 month 13.7
Extreme 13.7
25.35
Current year 13.7
Extreme 13.7
36
1 year 13.7
Extreme 13.7
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-04
Director of Finance/CFO 59 2022-08-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 64 2001-12-31
Director/Board Member 70 2019-04-10
Director/Board Member 62 2022-03-31
Date Insider Type Main position Quantity % Market Cap.
9/4/25 Buy

Chief Executive Officer

6 0.0000%
9/4/25 Free

Chief Executive Officer

1,393 0.0040%
9/3/25 Free 149 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+1.10%-3.15%-28.35%-16.52% 53.39M
-0.44%-0.53%+58.76%+22.05% 321B
+1.12%+3.70%+30.83%-9.70% 71.5B
+0.02%+3.04%+38.65%+90.79% 9.88B
-3.60%-2.43%-1.64%-5.95% 8.7B
+2.65%+1.04%-23.09%-5.02% 4.25B
+5.26%+5.41%-38.54%+12.12% 3.86B
-3.86%-8.18%-12.14%-2.26% 3.47B
-2.06%-3.35%+35.91%+49.93% 2.65B
-0.68%+4.52%-4.75%-5.33% 2.23B
Average +0.01%+1.17%+5.56%+13.01% 42.72B
Weighted average by Cap. -0.10%+4.46%+49.64%+17.23%

Financials

2026 *2027 *
Net sales 19M 1.99M 1.73M 1.6M 1.48M 2.79M 190M 2.84M 7.44M 94.34M 7.47M 7.31M 317M 27.5M 2.88M 2.5M 2.32M 2.14M 4.04M 275M 4.11M 10.77M 137M 10.81M 10.58M 459M
Net income -375M -39.27M -34.11M -31.68M -29.21M -55.03M -3.75B -56.02M -147M -1.86B -147M -144M -6.26B -270M -28.33M -24.6M -22.85M -21.07M -39.69M -2.7B -40.41M -106M -1.34B -106M -104M -4.52B
Net Debt -105M -11M -9.55M -8.87M -8.18M -15.41M -1.05B -15.69M -41.11M -521M -41.29M -40.39M -1.75B -143M -14.97M -13.01M -12.08M -11.14M -20.98M -1.43B -21.36M -55.99M -710M -56.24M -55M -2.39B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
26-07-31 SEK 14.76 +1.10% 11,996
26-07-30 SEK 14.60 +1.67% 108,507
26-07-29 SEK 14.36 -4.90% 63,413
26-07-28 SEK 15.10 0.00% 21,941
26-07-27 SEK 15.10 -0.92% 51,217
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise